Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015

Autores
Tabesh, Maryam; Magliano, D. J.; Tanamas, S. K.; Surmont, F.; Bahendeka, S.; Chiang, C. E.; Elgart, Jorge Federico; Gagliardino, Juan Jose; Kalra, Sanjay; Krishnamoorthy, S.; Luk, Andrea; Maegawa, H.; Motala, A. A.; Pirie, F.; Ramachandran, A.; Tayeb, K.; Vikulova, O.; Wong, J.; Shaw, J. E.
Año de publicación
2019
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Aim: Optimal treatment of cardiovascular disease is essential to decrease mortality among people with diabetes, but information is limited on how actual treatment relates to guidelines. We analysed changes in therapeutic approaches to anti-hypertensive and lipid-lowering medications in people with Type 2 diabetes from 2006 and 2015. Methods: Summary data from clinical services in seven countries outside North America and Western Europe were collected for 39 684 people. Each site summarized individual-level data from outpatient medical records for 2006 and 2015. Data included: demographic information, blood pressure (BP), total cholesterol levels and percentage of people taking statins, anti-hypertensive medication (angiotensin-converting enzyme inhibitors, calcium channel blockers, angiotensin II receptor blockers, thiazide diuretics) and antiplatelet drugs. Results: From 2006 to 2015, mean cholesterol levels decreased in six of eight sites (range: −0.5 to −0.2), whereas the proportion with BP levels > 140/90 mmHg increased in seven of eight sites. Decreases in cholesterol paralleled increases in statin use (range: 3.1 to 47.0 percentage points). Overall, utilization of anti-hypertensive medication did not change. However, there was an increase in the use of angiotensin II receptor blockers and a decrease in angiotensin-converting enzyme inhibitors. The percentage of individuals receiving calcium channel blockers and aspirin remained unchanged. Conclusions: Our findings indicate that control of cholesterol levels improved and coincided with increased use of statins. The percentage of people with BP > 140/90 mmHg was higher in 2015 than in 2006. Hypertension treatment shifted from using angiotensin-converting enzyme inhibitors to angiotensin II receptor blockers. Despite the potentially greater tolerability of angiotensin II receptor blockers, there was no associated improvement in BP levels.
Fil: Tabesh, M.. Monash University; Australia
Fil: Magliano, D.J.. Baker Heart And Diabetes Institute; Australia
Fil: Tanamas, S.K.. Baker Heart And Diabetes Institute; Australia
Fil: Surmont, F.. Monash University; Australia
Fil: Bahendeka, S.. Baker Heart And Diabetes Institute; Australia
Fil: Chiang, C.-E.. Astrazeneca;
Fil: ELGART, JORGE FEDERICO. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); Argentina
Fil: Gagliardino, Juan Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); Argentina
Fil: Kalra, S.. Centro de Endocrinología Experimental y Aplicada (conicet- Universidad Nacional de la Plata); Argentina
Fil: Krishnamoorthy, S.. Centro de Endocrinología Experimental y Aplicada (conicet- Universidad Nacional de la Plata); Argentina
Fil: Luk, A.. Bharti Hospital; India
Fil: Maegawa, H.. Dr. A Ramachandran's Diabetes Hospitals; India
Fil: Motala, A.A.. Prince Of Wales Hospital Hong Kong; Hong Kong
Fil: Pirie, F.. Shiga University Of Medical Science;
Fil: Ramachandran, A.. University Of Kwazulu-natal;
Fil: Tayeb, K.. University Of Kwazulu-natal;
Fil: Vikulova, O.. Dr. A Ramachandran's Diabetes Hospitals; India
Fil: Wong, J.. Al Noor Specialist Hospital;
Fil: Shaw, J.E.. Endocrinology Research Centre;
Materia
cardiovascular
diabetes
North America
Western Europe
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/94950

id CONICETDig_e0d6442899f72144080f88cf2f0ff8b9
oai_identifier_str oai:ri.conicet.gov.ar:11336/94950
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015Tabesh, MaryamMagliano, D. J.Tanamas, S. K.Surmont, F.Bahendeka, S.Chiang, C. E.Elgart, Jorge FedericoGagliardino, Juan JoseKalra, SanjayKrishnamoorthy, S.Luk, AndreaMaegawa, H.Motala, A. A.Pirie, F.Ramachandran, A.Tayeb, K.Vikulova, O.Wong, J.Shaw, J. E.cardiovasculardiabetesNorth AmericaWestern Europehttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Aim: Optimal treatment of cardiovascular disease is essential to decrease mortality among people with diabetes, but information is limited on how actual treatment relates to guidelines. We analysed changes in therapeutic approaches to anti-hypertensive and lipid-lowering medications in people with Type 2 diabetes from 2006 and 2015. Methods: Summary data from clinical services in seven countries outside North America and Western Europe were collected for 39 684 people. Each site summarized individual-level data from outpatient medical records for 2006 and 2015. Data included: demographic information, blood pressure (BP), total cholesterol levels and percentage of people taking statins, anti-hypertensive medication (angiotensin-converting enzyme inhibitors, calcium channel blockers, angiotensin II receptor blockers, thiazide diuretics) and antiplatelet drugs. Results: From 2006 to 2015, mean cholesterol levels decreased in six of eight sites (range: −0.5 to −0.2), whereas the proportion with BP levels > 140/90 mmHg increased in seven of eight sites. Decreases in cholesterol paralleled increases in statin use (range: 3.1 to 47.0 percentage points). Overall, utilization of anti-hypertensive medication did not change. However, there was an increase in the use of angiotensin II receptor blockers and a decrease in angiotensin-converting enzyme inhibitors. The percentage of individuals receiving calcium channel blockers and aspirin remained unchanged. Conclusions: Our findings indicate that control of cholesterol levels improved and coincided with increased use of statins. The percentage of people with BP > 140/90 mmHg was higher in 2015 than in 2006. Hypertension treatment shifted from using angiotensin-converting enzyme inhibitors to angiotensin II receptor blockers. Despite the potentially greater tolerability of angiotensin II receptor blockers, there was no associated improvement in BP levels.Fil: Tabesh, M.. Monash University; AustraliaFil: Magliano, D.J.. Baker Heart And Diabetes Institute; AustraliaFil: Tanamas, S.K.. Baker Heart And Diabetes Institute; AustraliaFil: Surmont, F.. Monash University; AustraliaFil: Bahendeka, S.. Baker Heart And Diabetes Institute; AustraliaFil: Chiang, C.-E.. Astrazeneca;Fil: ELGART, JORGE FEDERICO. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); ArgentinaFil: Gagliardino, Juan Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); ArgentinaFil: Kalra, S.. Centro de Endocrinología Experimental y Aplicada (conicet- Universidad Nacional de la Plata); ArgentinaFil: Krishnamoorthy, S.. Centro de Endocrinología Experimental y Aplicada (conicet- Universidad Nacional de la Plata); ArgentinaFil: Luk, A.. Bharti Hospital; IndiaFil: Maegawa, H.. Dr. A Ramachandran's Diabetes Hospitals; IndiaFil: Motala, A.A.. Prince Of Wales Hospital Hong Kong; Hong KongFil: Pirie, F.. Shiga University Of Medical Science;Fil: Ramachandran, A.. University Of Kwazulu-natal;Fil: Tayeb, K.. University Of Kwazulu-natal;Fil: Vikulova, O.. Dr. A Ramachandran's Diabetes Hospitals; IndiaFil: Wong, J.. Al Noor Specialist Hospital;Fil: Shaw, J.E.. Endocrinology Research Centre;Wiley Blackwell Publishing, Inc2019-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/94950Tabesh, Maryam; Magliano, D. J.; Tanamas, S. K.; Surmont, F.; Bahendeka, S.; et al.; Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015; Wiley Blackwell Publishing, Inc; Diabetic Medicine; 36; 7; 7-2019; 878-8870742-3071CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1111/dme.13858info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/full/10.1111/dme.13858info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:45:08Zoai:ri.conicet.gov.ar:11336/94950instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:45:09.177CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015
title Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015
spellingShingle Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015
Tabesh, Maryam
cardiovascular
diabetes
North America
Western Europe
title_short Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015
title_full Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015
title_fullStr Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015
title_full_unstemmed Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015
title_sort Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015
dc.creator.none.fl_str_mv Tabesh, Maryam
Magliano, D. J.
Tanamas, S. K.
Surmont, F.
Bahendeka, S.
Chiang, C. E.
Elgart, Jorge Federico
Gagliardino, Juan Jose
Kalra, Sanjay
Krishnamoorthy, S.
Luk, Andrea
Maegawa, H.
Motala, A. A.
Pirie, F.
Ramachandran, A.
Tayeb, K.
Vikulova, O.
Wong, J.
Shaw, J. E.
author Tabesh, Maryam
author_facet Tabesh, Maryam
Magliano, D. J.
Tanamas, S. K.
Surmont, F.
Bahendeka, S.
Chiang, C. E.
Elgart, Jorge Federico
Gagliardino, Juan Jose
Kalra, Sanjay
Krishnamoorthy, S.
Luk, Andrea
Maegawa, H.
Motala, A. A.
Pirie, F.
Ramachandran, A.
Tayeb, K.
Vikulova, O.
Wong, J.
Shaw, J. E.
author_role author
author2 Magliano, D. J.
Tanamas, S. K.
Surmont, F.
Bahendeka, S.
Chiang, C. E.
Elgart, Jorge Federico
Gagliardino, Juan Jose
Kalra, Sanjay
Krishnamoorthy, S.
Luk, Andrea
Maegawa, H.
Motala, A. A.
Pirie, F.
Ramachandran, A.
Tayeb, K.
Vikulova, O.
Wong, J.
Shaw, J. E.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv cardiovascular
diabetes
North America
Western Europe
topic cardiovascular
diabetes
North America
Western Europe
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Aim: Optimal treatment of cardiovascular disease is essential to decrease mortality among people with diabetes, but information is limited on how actual treatment relates to guidelines. We analysed changes in therapeutic approaches to anti-hypertensive and lipid-lowering medications in people with Type 2 diabetes from 2006 and 2015. Methods: Summary data from clinical services in seven countries outside North America and Western Europe were collected for 39 684 people. Each site summarized individual-level data from outpatient medical records for 2006 and 2015. Data included: demographic information, blood pressure (BP), total cholesterol levels and percentage of people taking statins, anti-hypertensive medication (angiotensin-converting enzyme inhibitors, calcium channel blockers, angiotensin II receptor blockers, thiazide diuretics) and antiplatelet drugs. Results: From 2006 to 2015, mean cholesterol levels decreased in six of eight sites (range: −0.5 to −0.2), whereas the proportion with BP levels > 140/90 mmHg increased in seven of eight sites. Decreases in cholesterol paralleled increases in statin use (range: 3.1 to 47.0 percentage points). Overall, utilization of anti-hypertensive medication did not change. However, there was an increase in the use of angiotensin II receptor blockers and a decrease in angiotensin-converting enzyme inhibitors. The percentage of individuals receiving calcium channel blockers and aspirin remained unchanged. Conclusions: Our findings indicate that control of cholesterol levels improved and coincided with increased use of statins. The percentage of people with BP > 140/90 mmHg was higher in 2015 than in 2006. Hypertension treatment shifted from using angiotensin-converting enzyme inhibitors to angiotensin II receptor blockers. Despite the potentially greater tolerability of angiotensin II receptor blockers, there was no associated improvement in BP levels.
Fil: Tabesh, M.. Monash University; Australia
Fil: Magliano, D.J.. Baker Heart And Diabetes Institute; Australia
Fil: Tanamas, S.K.. Baker Heart And Diabetes Institute; Australia
Fil: Surmont, F.. Monash University; Australia
Fil: Bahendeka, S.. Baker Heart And Diabetes Institute; Australia
Fil: Chiang, C.-E.. Astrazeneca;
Fil: ELGART, JORGE FEDERICO. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); Argentina
Fil: Gagliardino, Juan Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); Argentina
Fil: Kalra, S.. Centro de Endocrinología Experimental y Aplicada (conicet- Universidad Nacional de la Plata); Argentina
Fil: Krishnamoorthy, S.. Centro de Endocrinología Experimental y Aplicada (conicet- Universidad Nacional de la Plata); Argentina
Fil: Luk, A.. Bharti Hospital; India
Fil: Maegawa, H.. Dr. A Ramachandran's Diabetes Hospitals; India
Fil: Motala, A.A.. Prince Of Wales Hospital Hong Kong; Hong Kong
Fil: Pirie, F.. Shiga University Of Medical Science;
Fil: Ramachandran, A.. University Of Kwazulu-natal;
Fil: Tayeb, K.. University Of Kwazulu-natal;
Fil: Vikulova, O.. Dr. A Ramachandran's Diabetes Hospitals; India
Fil: Wong, J.. Al Noor Specialist Hospital;
Fil: Shaw, J.E.. Endocrinology Research Centre;
description Aim: Optimal treatment of cardiovascular disease is essential to decrease mortality among people with diabetes, but information is limited on how actual treatment relates to guidelines. We analysed changes in therapeutic approaches to anti-hypertensive and lipid-lowering medications in people with Type 2 diabetes from 2006 and 2015. Methods: Summary data from clinical services in seven countries outside North America and Western Europe were collected for 39 684 people. Each site summarized individual-level data from outpatient medical records for 2006 and 2015. Data included: demographic information, blood pressure (BP), total cholesterol levels and percentage of people taking statins, anti-hypertensive medication (angiotensin-converting enzyme inhibitors, calcium channel blockers, angiotensin II receptor blockers, thiazide diuretics) and antiplatelet drugs. Results: From 2006 to 2015, mean cholesterol levels decreased in six of eight sites (range: −0.5 to −0.2), whereas the proportion with BP levels > 140/90 mmHg increased in seven of eight sites. Decreases in cholesterol paralleled increases in statin use (range: 3.1 to 47.0 percentage points). Overall, utilization of anti-hypertensive medication did not change. However, there was an increase in the use of angiotensin II receptor blockers and a decrease in angiotensin-converting enzyme inhibitors. The percentage of individuals receiving calcium channel blockers and aspirin remained unchanged. Conclusions: Our findings indicate that control of cholesterol levels improved and coincided with increased use of statins. The percentage of people with BP > 140/90 mmHg was higher in 2015 than in 2006. Hypertension treatment shifted from using angiotensin-converting enzyme inhibitors to angiotensin II receptor blockers. Despite the potentially greater tolerability of angiotensin II receptor blockers, there was no associated improvement in BP levels.
publishDate 2019
dc.date.none.fl_str_mv 2019-07
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/94950
Tabesh, Maryam; Magliano, D. J.; Tanamas, S. K.; Surmont, F.; Bahendeka, S.; et al.; Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015; Wiley Blackwell Publishing, Inc; Diabetic Medicine; 36; 7; 7-2019; 878-887
0742-3071
CONICET Digital
CONICET
url http://hdl.handle.net/11336/94950
identifier_str_mv Tabesh, Maryam; Magliano, D. J.; Tanamas, S. K.; Surmont, F.; Bahendeka, S.; et al.; Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015; Wiley Blackwell Publishing, Inc; Diabetic Medicine; 36; 7; 7-2019; 878-887
0742-3071
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1111/dme.13858
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/full/10.1111/dme.13858
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley Blackwell Publishing, Inc
publisher.none.fl_str_mv Wiley Blackwell Publishing, Inc
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614490273873920
score 13.070432